LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Chemomab Therapeutics Ltd.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCMMB
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CMMB COVERAGE

What’s moving Chemomab Therapeutics Ltd. now

Current reporting with the operating signal separated from the noise.

01
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

The story matters when it changes Chemomab Therapeutics Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial ...

Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial ...

The development tests whether Chemomab Therapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
03
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript

Investors are testing whether Chemomab Therapeutics Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Investors are testing whether Chemomab Therapeutics Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) drops to US$102m and insiders who purchased earlier this year lose another US$78k

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) drops to US$102m and insiders who purchased earlier this year lose another US$78k

The story matters when it changes Chemomab Therapeutics Ltd.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
What Type Of Shareholders Own The Most Number of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Shares?

What Type Of Shareholders Own The Most Number of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Shares?

Investors are testing whether Chemomab Therapeutics Ltd.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CMMB filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2023-05-11 · Period 2023-03-31SEC ↗10-QQuarterly financial reportFiled 2022-11-10 · Period 2022-09-30SEC ↗10-KAnnual financial reportFiled 2023-03-20 · Period 2022-12-31SEC ↗8-KMaterial company eventFiled 2023-06-16 · Period 2023-06-14SEC ↗8-KMaterial company eventFiled 2023-06-05 · Period 2023-06-01SEC ↗8-KMaterial company eventFiled 2023-05-11 · Period 2023-05-11SEC ↗6-KOfficial SEC filingFiled 2026-07-08 · Period 2026-07-08SEC ↗6-KOfficial SEC filingFiled 2026-06-02 · Period 2026-06-02SEC ↗
EARNINGS / QUARTERLY TRACKER

Chemomab Therapeutics Ltd., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.